BRIEF—Araris Biotech gets funding from Samsung Ventures

Swiss biotech Araris Biotech today announced that Samsung Venture Investment Corporation has invested in the company in an independent deal ahead of its on-going series A funding.

Araris is pioneering a proprietary antibody-drug conjugate (ADC)-linker technology.

The investment was made via Samsung Life Science Fund – created jointly between Samsung Biologics and Samsung C&T, and managed by Samsung Ventures – which reflects Samsung’s commitment to further explore and expand various business opportunities in biopharmaceuticals.

The latest investment reflects Samsung’s commitment to further expanding its pipeline.

As a strategic investor, Samsung will collaborate on evaluating, manufacturing and developing assets with Araris using the company’s proprietary ADC Technology, in close collaboration with Samsung affiliates involved in the discovery and development, and manufacturing of novel biologics.

“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, chief executive of Samsung Biologics.